

# ForPatients

by Roche

Solid Tumors Cancer

## A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors

**Trial Status**  
Completed

**Trial Runs In**  
6 Countries

**Trial Identifier**  
NCT02304393 2014-002835-32  
BP29392

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### ***Trial Summary:***

This is an open-label, multicenter study designed to assess the safety, pharmacokinetics, pharmacodynamics and activity of Selicrelumab administered in combination with Atezolizumab (ATZ) in participants with metastatic or locally advanced solid tumors. The study will be conducted in two Parts (I and II), with Part I divided into Parts IA and IB. All participants will be followed up for survival until death or loss of follow-up after the last visit or withdrawal of consent.

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

---

**NCT02304393 2014-002835-32 BP29392**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥ 18 Years

**Healthy Volunteers**  
No

---